1 2 3 4
News & Information
Prostate Cancer: ADT Plus Docetaxel May Improve 12-Month Quality of Life

Androgen-deprivation therapy (ADT) with docetaxel may improve quality of life (QoL) at 12 months among patients with metastatic hormone-sensitive prostate cancer

Webcast: Prostate Cancer Clinical Trials Creating New Treatment Options For Patients Webcast: Prostate Cancer Clinical Trials Creating New Treatment Options For Patients

Dr. Mary-Ellen Taplin, Dana-Farber Cancer Institute, will review recent FDA approved treatment options and the clinical trials that were responsible for these important breakthroughs. 
FDA approves abiraterone acetate in combination with prednisone

FDA approved abiraterone acetate tablets in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer.

Xtandi Reduces Risk of Metastasis in Castration-resistant Prostate Cancer

Treatment with Xtandi (enzalutamide) reduced the risk of metastasis or death in castration-resistant prostate cancer (CRPC) patients whose cancer has not yet spread beyond the prostate.

Patients should Patients should "Ask-In" on clinical trials participation

African American participation in prostate cancer clinical trials must move from 3-5% range to 10-12% range to determine the effectiveness of new treatments.

FDA Approves Apalutamide: the first treatment for non-metastatic castration-resistant prostate cancer

The U.S. Food and Drug Administration (FDA) approved apalutamide for the treatment of non-metastatic castration-resistant prostate cancer 

Two new treatments have been found for prostate cancer patients who previously had no effective treatment options

Clinical trials have found that Enzalutamide and Apalutamide are both able to significantly delay prostate cancer progression in men with non-metastatic castration-resistant prostate cancer.